SCHEMBL27779372

SCHEMBL27779372

O=C(Cc1ccccc1O)OC1CCCC1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 4/20 0.53
ALDH1A1 P00352 3/20 0.50
KDM4E B2RXH2 2/20 0.50
HPGD P15428 2/20 0.50
AKR1B1 P15121 1/20 0.50
HSD17B10 Q99714 1/20 0.50
LMNA P02545 2/20 0.40
RAB9A P51151 1/20 0.40
SIGMAR1 Q99720 1/20 0.40
FABP7 O15540 1/20 0.39
FABP5 Q01469 1/20 0.39
BCHE P06276 1/20 0.39
CACNA1B Q00975 1/20 0.38
HSPA5 P11021 1/20 0.38
CYP2C19 P33261 1/20 0.38
NAAA Q02083 1/20 0.38
MIF P14174 1/20 0.38
EPHX1 P07099 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6354197 0.80 AKR1B1 (0.42) ALDH1A1KDM4EHPGDAKR1B1HSD17B10
SCHEMBL5049441 0.78 CYP19A1 (0.71) CYP19A1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL6411668 0.78 AKR1B1 (0.44) ALDH1A1KDM4EHPGDAKR1B1HSD17B10
SCHEMBL27562521 0.77 THRA (0.46) ALDH1A1KDM4EHPGDAKR1B1HSD17B10
SCHEMBL1301606 0.77 CYP19A1 (0.71) CYP19A1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL27820726 0.77 CYP19A1 (0.71) CYP19A1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL29349625 0.75 AKR1B1 (0.65) AKR1B1HSPA5
SCHEMBL2228365 0.75 AKR1B1 (0.65) AKR1B1HSPA5
SCHEMBL6761969 0.75 CYP19A1 (0.66) CYP19A1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL17684940 0.73 CYP19A1 (0.63) CYP19A1ALDH1A1KDM4EHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101663270-A Quaternary ammonium compounds useful as muscarinic receptor antagonists THERAVANCE INC 2010-03-03 CN disclosed